Special Issue

New Insights into Breast Cancer Management: From Tumorigenesis to Personalized Treatments—2nd Edition

Message from the Guest Editors

Breast cancer is a very heterogeneous disease with multifactorial etiopathogenesis. In the last few decades. a deeper understanding of the molecular mechanisms underlying breast cancer development and progression has led to the development of novel accurate prognostic analyses and new effective drugs, thus leading to increased overall survival for breast cancer patients. Nevertheless, breast cancer remains the second leading cause of death in women globally. Thus, there is still a need to better understand the complexity of breast cancer and the interaction between the neoplasm and its microenvironment, as well as the immune system, to prevent disease development and to guide personalized treatments. Moreover, since individual response to therapy and long-term prognosis remain highly unpredictable, the current context requires identifying biomarkers that accurately forecast the response to therapy and identify patients who will not benefit from standard regimens. On the other hand, since the number of breast cancer survivors is continuously increasing, understanding the complexity of breast cancer survivorship is essential for adequate patient management.

Guest Editors

Dr. Rita De Sanctis

Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, 20090 Milan, Italy

Dr. Paola Tiberio

Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy

Deadline for manuscript submissions

28 February 2026



an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/250152

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).